SANTA CRUZ BIOTECHNOLOGY, INC.

5α-Reductase 2 (1F4): sc-293232



The Tower to ques

BACKGROUND

Steroid 5 α -Reductase is an important enzyme in androgen physiology because it catalyzes the conversion of testosterone into the more potent 5 α -dihydrotestosterone, which mediates androgen effects on target tissues. The enzyme exists as two isoforms: type 1, which is expressed mainly in the skin; and type 2, which is expressed mainly in the prostate. In cultured human skin cells, 5 α -Reductase 1 shows heterogeneity of protein, and has different levels of transcriptional and translational expression. 5 α -Reductase 1 is expressed in all portions of the hair follicle, whereas 5 α -Reductase 2 is expressed only in mesenchymal portions. In addition, 5 α -Reductase 1 is mainly expressed in human breast carcinoma and may play a role in the *in situ* production and actions of the potent androgen 5 α -dihydrotestosterone, including inhibition of cancer cell proliferation in hormone-dependent human breast carcinoma. The 5 α -Reductase-3 α -hydroxysteroid dehydrogenase complex is present in the human brain, suggesting that the complex may be involved in the synthesis of neuroactive steroids or the catabolism of neurotoxic steroids.

REFERENCES

- 1. Bonkhoff, H., et al. 1996. Differential expression of 5α -Reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29: 261-267.
- 2. Taylor, M.F., et al. 1997. Expression of rat steroid 5α -Reductase (isozyme-1) in *Spodoptera frugiperda*, SF21, insect cells: expression of rat steroid 5α -Reductase. Steroids 62: 373-378.
- 3. Chen, W., et al. 1998. Evidence of heterogeneity and quantitative differences of the type 1 5α -Reductase expression in cultured human skin cells—evidence of its presence in melanocytes. J. Invest. Dermatol. 110: 84-89.
- Suzuki, T., et al. 2001. 5α-Reductases in human breast carcinoma: possible modulator of *in situ* androgenic actions. J. Clin. Endocrinol. Metab. 86: 2250-2257.
- 5. Steckelbroeck, S., et al. 2001. Characterization of the 5α -Reductase- 3α -hydroxysteroid dehydrogenase complex in the human brain. J. Clin. Endocrinol. 86: 1324-1331.

CHROMOSOMAL LOCATION

Genetic locus: SRD5A2 (human) mapping to 2p23.1.

SOURCE

 $5\alpha\text{-Reductase}$ 2 (1F4) is a mouse monoclonal antibody raised against amino acids 28-65 of $5\alpha\text{-Reductase}$ 2 of human origin.

PRODUCT

Each vial contains 100 μg lgG_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

 5α -Reductase 2 (1F4) is recommended for detection of 5α -Reductase 2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Suitable for use as control antibody for 5α -Reductase 2 siRNA (h): sc-41398, 5α -Reductase 2 shRNA Plasmid (h): sc-41398-SH and 5α -Reductase 2 shRNA (h) Lentiviral Particles: sc-41398-V.

Molecular Weight of 5α-Reductase 2: 28 kDa

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

DATA



 $5\alpha\text{-Reductase 2 (1F4): sc-293232.}$ Western blot analysis of human recombinant $5\alpha\text{-Reductase 2 fusion protein.}$

SELECT PRODUCT CITATIONS

- Jang, J., et al. 2021. Resveratrol attenuates the proliferation of prostatic stromal cells in benign prostatic hyperplasia by regulating cell cycle progression, apoptosis, signaling pathways, BPH markers, and NFκB activity. Int. J. Mol. Sci. 22: 5969.
- D'Amico, R., et al. 2021. Palmitoylethanolamide/baicalein regulates the androgen receptor signaling and NFκB/Nrf2 pathways in benign prostatic hyperplasia. Antioxidants 10: 1014.
- Horwath, O., et al. 2022. Molecular regulators of muscle mass and mitochondrial remodeling are not influenced by testosterone administration in young women. Front. Endocrinol. 13: 874748.
- Jang, Y.J., et al. 2023. Effects of alginate oligosaccharide on testosteroneinduced benign prostatic hyperplasia in orchiectomized rats. Nutrients 15: 682.

RESEARCH USE

For research use only, not for use in diagnostic procedures.